EuroSciCon

Cancer Research, Survivorship & Management

August 22-23
Tokyo, Japan

2019



Cancer Research 2019

www.cancer.euroscicon.com

Day 1, Agenda

General Session

08:00 AM — INTRODUCTION

09:00 AM — PLENARY

10:00 AM — KEYNOTE

Networking & Refreshments Break @ Foyer

	HALL 01	HALL 02	HALL 03
11:00 AM	Talks On: **Cancer Research**	Talks On: **Cancer Genetics**	Talks On: **Cancer Epigenetics**
	Talks On: **Evade Apoptosis**	Talks On: **Adenomatous polyposis**	Talks On: **Prostate Cancer**
	SESSION DISCUSSION	**SESSION DISCUSSION**	**SESSION DISCUSSION**
02:00 PM	Panel Over: **Cancer Science**	Panel Over: **Cancer Diagnostics**	Panel Over: **Cancer Therapies & Prevention**
	Workshop On: **Molecular Oncology**	Workshop On: **Methods of Cancer Diagnostics**	Workshop On: **Nano-medicine Therapy**
	Lunch Break @ Restaurant	***Lunch Break @ Restaurant***	***Lunch Break @ Restaurant***
04:00 PM	Talks On: **Cancer Stem Cells**	Talks On: **Biomarkers**	Talks On: **Biopsy**
	Lectures on: **De-differentiation Cancer cells**	Lectures on: **Hyphenated Techniques**	Lectures on: **Risks of a biopsy**
06:00 PM	Session On: **Chemotherapy**	Session On: **Cancer screening**	Session On: **Cancer Immunotherapy**
	NETWORKING	**NETWORKING**	**NETWORKING**

Day 2, Agenda

General Session

08:00 AM — INTRODUCTION

09:00 AM — PLENARY

10:00 AM — KEYNOTE

Networking & Refreshments Break @ Foyer

	HALL 01	HALL 02	HALL 03
11:00 AM	Talks On: **Cancer Operomics**	Talks On: **Carcinogenesis**	Talks On: **Cancer Nursing Care**
	Talks On: **Biopsy**	Talks On: **Sensitile Lymph node Mapping**	Talks On: **Surgical Biopsy**
	SESSION DISCUSSION	**SESSION DISCUSSION**	**SESSION DISCUSSION**
02:00 PM	Panel Over: **Genetic Translation Process**	Panel Over: **Oncoranvirus Expression**	Panel Over: **Symptom Management**
	Workshop On: **Cancer Awareness**	Workshop On: **Experimental Therapeutics**	Workshop On: **Organ-specific Cancer**
	Lunch Break @ Restaurant	***Lunch Break @ Restaurant***	***Lunch Break @ Restaurant***
04:00 PM	Talks On: **Clinical DNA Sequencing**	Talks On: **Bone Marrow Transplantation**	Talks On: **Emerging Personalized Medicine**
	Lectures on: **Radiation Therapy**	Lectures on: **Cancer Alternative Medicine**	Lectures on: **Cancer Survivors**
06:00 PM	Session On: **Malignancy Aggravation**	Session On: **Personalized Medicine**	Session On: **Market analysis of cancer diagnostics**
	NETWORKING	**NETWORKING**	**NETWORKING**

Past Affiliates

Melissa Joyner
The University of Texas, USA

William Jia
University of British Columbia, Canada

Chiung-Fang Chang
Far Eastern Memorial Hospital

Adrian Senderowicz
Cerulean Pharma, USA

Qiaofei Liu
Peking Union Medical College Hospital, China

Han-Heom Na
Kangwon National University, South Korea

Vincent Balaya
University Paris Descartes, France

Lidija Covic
Tufts Medical Center, USA

Jaecheong Lim
Korea Atomic Energy Research Institute, South Korea

Xueqing Wang
Beijing Jishuitan Hospital, China

Shahla Masood
UF Health Breast Center, USA

Darya Tsvirkun
The Hebrew University of Jerusalem

Xudong Miao
Zhejiang University, China

Gaiane M. Rauch
University of Texas Cancer Center, USA

Surangkana Sanmai
Khon Kaen University

Michael R Olin
University of Minnesota, USA

Michael Thompson
University of Wroclaw,Canada

Katarina Jeremić
Belgrade University School of Medicine

Raushan Kurmasheva
University of Texas Health Science Center, USA

Emmanuelle Charafe-Jauffret
University of Mediterranée, France

Hazan Ozyurt
Lutfi Kirdar Kartal Education and Research Hospital

Norbert Graf
Saarland University, Germany

Chang Gong
Sun Yat-Sen University, China

Kennedy Gonçalves Pacheco
Vascular Surgeon and Phlebologist

Liqin Du
Texas State University, USA

Ragheed Al-Mufti
The West of London Breast Cancer Network, UK

Tevfik Guvenal
Celal Bayar University School of Medicine

Ravi Radhakrishnan
University of Pennsylvania, USA

Maude Hébert
University of Quebec in Trois-Rivieres, Canada

Vineet Talwar
Rajiv Gandhi Cancer Institute and Research Centre

Past Affiliates

Christian G. Chaussy
University Regensburg,Germany , Germany

Guan Chen
Medical College of Wisconsin, USA

Aleksandar Stefanović
Association of gynecologist and obstetricians of Serbia

KN Leung
Chinese University of Hong Kong, China

M.A. Nezami MD
Pacific Medical Center of Hope, United States

Tommy Nai-Jen Chang
Chang Gung Memorial Hospital

Gregory G. Passmore
Augusta University, United States, USA

Mouad Edderkaou
Cedars-Sinai Medical Center, USA

Hossam El Sokkary
Alexandria university

Jim Burgess
Augusta University United States, United States

Yiu-Lian Fong
Johnson & Johnson Innovation, UK

Somashekhar S.P
Manipal Hospital

Zoya Vinokur
New York City College of Technology, USA

Karl R Aigner
Medias Klinikum GmbH & Co. KG

Kannan Vaidyanathan
Pushpagiri Institute of Medical Science & Research Center

Benedict Benigno
Ovarian Cancer Institute, USA

Alireza Heidari
Professor, USA

Georgios Stamatakos
National Technical University of Athens

Sang Y Lee
Penn State Health Milton S. Hershey Medical Center, USA

MA Nezami
President, USA

Elizabeth Algar
Hudson Institute of Medical Research, Australia

Jan Lewin
University of Texas MD Anderson Cancer Center, USA

Sputova K
University of Miami Miller School of Medicine, USA

Ines Vasconcelos
Berlin Oncological Center Kurfürstendamm, Germany

Hiroshi Osawa
Edogawa Hospital, Japan

Nematallah Mansour
Université de Sherbrooke, Canada

Nalini Kant Pati
Australian National University, Australia

Saad Kenderian
Mayo Clinic,USA

Omer Kucuk
Emory University, USA

Nahla Ali Mobark
King Fahad Medical City

Thomas Mehrling CEO
Mundipharma EDO GmbH, Switzerland

Qun Lu
East Carolina University, USA

Jessy S Deshane
University of Alabama at Birmingham, USA

Past Affiliates

Giuseppe Leone
Catholic University

Taisei Nomura
Osaka University, Japan

Ines Vasconcelos
Berlin Oncological Center Kurfürstendamm, Germany

David J. Bearss CEO
Tolero Pharmaceuticals, USA

Jennifer L Young
The Urology Group, USA

Michael G Hanna
Vaccinogen Inc., USA

Jack Sariego
Aria-Jefferson Health System, USA

Lucia R Languino
Thomas Jefferson University, USA

María del Rosario Dávalos Gamboa
University of San Simón

Ashutosh Kothari
Guys Hospital, UK

Jiao Zhang
East Carolina University, USA

Ines Vasconcelos
Berlin Oncological Center Kurfürstendamm, Germany

Hong Zhang
University of Texas-M D Anderson Cancer Center, USA

Aejaz Sayeed
Thomas Jefferson University, USA

Alex Agyekum
Bikbok Herbal Centre

Yun Gong MD
Anderson Cancer Center, USA

Kristina Shahriari
Drexel University, USA

María Marcela Barrio
Centro de Investigaciones Oncológicas Fundación Cáncer

Sheldon Milstien
Virginia Commonwealth University, USA

Zhi Ping Xu
University of Queensland, Australia

Petrousjka van den Tol
VU University Medical Center

Senqing Chen
Jiangsu Institute of Cancer Research, China

David K. Imagawa
University of California, USA

Marco Bernini
Careggi University Hospital

Julia Gerasimenko
Cardiff University, UK

Rupinder Kaur
Deakin University, Australia

Baek Kwang-In
The institute of Koryo Acupotomology, Korea

Feng Yan
Nanjing Medical university Hospital, China

Veronica J James
Australian National University, Australia

Larysa M.Skivka
Professor, Ukraine

Andreas Lehmann
Fraunhofer Institute for Ceramic Technologies and Systems

Pascal H G Duijf
University of Queensland, Australia

Waleed Seif El-Din Mohamed Mostafa
Professor Cairo University

Past Affiliates

Juan F Roman
Cambridge Consultants Medical Technology, UK

Jagat R Kanwar
Deakin University, Australia

Mohamed EL-Far
Professor, Egypt

Oleg Gerasimenko
Cardiff University, UK

Susan J Done
University of Toronto, Canada

Bogusław Maciejewski
Director, Poland

Julia Gerasimenko
Cardiff University, UK

Igor Buchwalow
University of Muenster, Germany

David Huang
Professor, China

Jessy Deshane
University of Alabama at Birmingham, USA

Thomas Kieber-Emmons
University of Arkansas for Medical Science, USA

Nina Tuncel
Professor, Turkey

Andreas Lehmann
Fraunhofer Institute for Ceramic Technologies and Systems

Stefan B. Eichmüller
German Cancer Research Center, Germany

Bahram Mofid
Shahid Beheshti University of Medical Sciences

Jennifer Wu
Hollings Cancer Centre, USA

Raj Tiwari
New York Medical College, USA

Sheeba Jacob
Mumbai University

Peter Weightman
University of Liverpool, UK

Alex Dommann
Swiss Federal Laboratories for Materials Science and Technology,

Fahri Saatcioglu
Oslo University Hospital

Alok De
Kansas City Vet Center, USA

Niccola Funel
University of Pisa

Elif Damla
Istanbul Kultur University

Jeffrey B Ulmer
Novartis Vaccines & Diagnostics, USA

Wassil Nowicky
Ukrainian Anti-Cancer Institute

Guldeniz Karadeniz Cakmak
Bulent Ecevit University

Michael Goris
Stanford University School of Medicine, USA

Francesco Zinno
University of Rome Tor Vergata

Diptendra K Sarkar
Professor, IPGMER

Shuo Li
GE Healthcare, Canada

Jan Jacques Michiels
Goodheart Institute

Sadir Jumaa Alrawi
Tawam Cancer Centre

Past Affiliates

Leung KN
The Chinese University of Hong Kong, China

Shikai Wu
Academy of Military Medical Sciences, China

Deepak Kaul
Postgraduate Institute of Medical Education & Research, India

Morio Sato
Wakayama Medical University, Japan

Shahram Bahmanyar
Karolinska Institutet Stockholm, Sweden

Fritz Lahrtz
Isenbruck Bösl Hörschler LLP Prinzregentenstr, Germany

IkuoTooyama
Shiga University of Medical Science, Japan

Cohen-Armon
Tel-Aviv University

Yaffa Mizrachi Nebenzahl
Ben Gurion University of the Negev

Doungdean Tummanatsakun
Khon Kaen University

Anne Ryhänen
University of Turku

Mahmoud El-Foudeh
King Faisal Specialist Hospital & Research Center, Saudi Arabia


Kuo-Wang Tsai
Kaohsiung Veterans General Hospital

Hsu-Shan Huang
Taipei Medical University

Giulio Tarro
Foundation de Beaumont Bonelli for Cancer Research, Italy

Shahram Bahmanyar
Karolinska Institutet Stockholm, Sweden

Syed Rahmanuddin
Radiology Center City of Hope, USA



Plan a trip to Tokyo: Destination Of Cancer Research 2019

Tokyo was some time ago named Edo when Shōgun Tokugawa Ieyasu made the city as his home office in 1603. It turned into the capital after Emperor Meiji moved his seat to the city from Kyoto in 1868; around then Edo was renamed Tokyo. Tokyo Metropolis was shaped in 1943 from the merger of the previous Tokyo Prefecture. The city of Tokyo has 39 million occupants, half a greater number of individuals than some other urban region, with a $2.5 trillion economy bigger than that of some other city; in the event that it was a nation, Tokyo would be the eighth biggest economy on the planet. Tokyo is frequently alluded to as a city, however, is formally referred to and administered as a "metropolitan prefecture", which contrasts from and consolidates components of a city and a prefecture. The Tokyo Metropolitan Government directs the 23 Special Wards of Tokyo (each administered as an individual city), which cover the region that was the city of Tokyo before it consolidated and turned into the metropolitan prefecture in 1943, the 30 districts in the western piece of the prefecture, and the two remote island chains. The number of inhabitants in the exceptional wards is more than 9 million individuals, with the aggregate populace of the prefecture surpassing 13 million. Tokyo is positioned first in the Global Economic Power Index and third in the Global Cities Index.

Explore This Embodiment Tourist Heritage

Tokyo a city which comprises both modern architecture and historical monuments is a place worth visiting once in a lifetime. Following are the famous tourist marvels of the city





City Attractions









EuroSciCon

7th Edition of World Congress on Cancer Research, Survivorship and Management

AUGUST 22-23, 2019 | TOKYO, JAPAN

AGENDA

Abstract

EuroSciCon

Title: Incorporating Fuzzy Logic within Cancer Research to Help Improve Integrative Health Care and Chronic Disease Management

Kevin D. Willison
Lakehead University
Canada

Statement of the Problem: The administration of both health and social services, focused towards helping to meet the diverse care needs of cancer patients, typically necessitate on-going improvements in both coordination as well as collaboration amongst varied health care professionals. To this end incorporating principals of fuzzy logic appears to have potential utility. Fuzzy logic broadens Boolean logic conceptualizations of reality by going beyond such dichotomous alive/dead; disease/no disease types of thinking patterns. Hence, in using fuzzy logic, "exact" / binary style reasoning is shelved, favoring instead consideration of what lies between such indicators as above. In other words, fuzzy logic offers a way of thinking and doing that is more patient-centred and holistically inclined. Method, this review is based on a thorough scoping of the social and scientific literature, using such data bases as PubMed, Medline, PsycLIT and Sociofile. Chronic disease management (CDM) is defined here as an approach to health care that places emphasizes towards helping individuals maintain and/or maximize their independence and functional capacity, through the prevention, early detection and management of chronic disease. CDM initiatives typically place focus towards improving an individual's health-related quality of life. Findings: there appears to be sufficient support that

Title: Therapeutic efficacy of cancer stem cell vaccine

Qiao Li
University of Michigan
USA

The existence of micro-metastasis at the time of tumor resection represents a significant therapeutic challenge, since 90% of tumor deaths are due to tumor metastasis. Effective prevention of local and distant tumor recurrence remains to be developed. There is increasing evidence that many cancers are driven and maintained by cancer stem cells (CSCs) which contribute to tumor recurrence and metastasis. Targeting CSCs may thus increase the therapeutic efficacy of current cancer treatment. We described a strategy to target CSCs using CSC-dendritic cell (DC) vaccination. However, the efficacy of CSC targeted therapeutics may be greatest when they are deployed in the adjuvant setting. In this study, two mouse models were utilized: established s.c. SCC7 tumors were surgically removed from mice followed by treatment using ALDHhigh SCC7 CSC-DC vaccine, which significantly reduced local tumor relapse and prolonged animal survival.

Title: Highly efficient RNA-guided base-editing in mouse

Kyoungmi Kim
Korea University College of Medicine
South Korea

Point mutations caused by nucleobase deamination are a major source of human genetic disorders and diversity. Unlike mutagens causing random nucleobase deamination, RNA-programmable deaminase systems, composed of a catalytically impaired CRISPR–Cas9 variant (D10A Cas9 nickase (nCas9) or catalytically deficient D10A/H840A Cas9 (dCas9) from S. pyogenes) and a deaminase protein from various sources, enable single-nucleotide conversions or base editing in cells and organisms in a gRNA-dependent manner. These base editing systems can be divided into two categories: cytosine base editors (CBEs) that convert a C:G base pair to a T:A pair and Adenine base editors (ABEs) that convert a A:T pair to a G:C pair. Here we demonstrated the application of this technology in mouse embryos and adult mice.

SPEAKER SLOTS AVAILABLE

Abstract

EuroSciCon

Title: The Role of Ultrasound as a Diagnostic Tool for Breast Cancer in the Screening of Younger Women (Age 25-38) in Guyana

Felicia Devika Nandan
Cancer Institute of Guyana
Guyana

Ultrasound is used in many ways, not only as an initial diagnostic tool for confirmation of pathology determined from biopsies of the breast but also staging of breast cancer. Ultrasound is inexpensive and readily available almost all over the country. In a recent publication from the UK, the incidence of breast cancer in women younger than 35 years was 1.4% and in those younger than 30 years it was 0.43%. Breast Cancer is the most commonly diagnosed cancer amongst women worldwide. There were approximately 1.38 million new cases of breast cancer in the year 2008 and by 2020 this figure is anticipated to escalate to 1.7 million.

Title: A crosstalk between c-Myc and HIFα

Mian Wu
Nanjing Normal University
China

The oncoprotein c-Myc plays an important role in regulating glycolysis under normoxia; yet, in cancer cells, HIF1□, which is essential for driving glycolysis under hypoxia, is often up-regulated even in the presence of oxygen. The relationship between these two regulators of the Warburg effect remains undefined. Here we demonstrate that a long noncoding RNA (lncRNA), named IDH1-AS1, enables c-Myc to collaborate with HIF1□ in activating the Warburg effect under normoxia. Mechanistically, c-Myc transcriptionally represses IDH1-AS1, which, promotes dimerization of IDH1 and thus enhances its enzymatic activity. This results in increased □-KG that down-regulates HIF1□. Moreover, IDH1-AS1 overexpression inhibits, whereas silencing of IDH1-AS1 promotes cell proliferation and cancer xenograft growth. IDH1-AS1 may represent a potential metabolic approach for cancer treatment.

Title: The Challenge of the Prevention and Treatment of Cancers in View of the Global Metabolic Disease Problem and the Imprecision of "Precision Medicine

James E. Trosko
Michigan State University
USA

Within global concerns of "metabolic diseases", exposures to radiations, chemicals and microbial agents, the ineffective toxicological tests, the costly animal tests, governmental restrictions on animals for drug discovery and toxicity testing, new strategies are needed to reduce and treat these acute and chronic diseases. There is no universally acceptance of the mechanisms by which radiations, chemicals and microbial agents might contribute to the pathogenesis, prevention and treatment of human childhood diseases. Moreover, the emphasis on "Precision" or "Personalized" Medicine, together with the availability of sophisticated molecular technologies, is starting to generate tons of data, only to be analyzed by non-biologically-based algorisms.

SPEAKER SLOTS AVAILABLE

Abstract

EuroSciCon

Title: Should smoking cessation be a standard procedure in cancer care

Magdalena Cedzynska
The Maria Sklodowska-Curie Institute –Oncology Centre
Poland

Tobacco smoking is has been linked not only to the development of cancer (15 different sites), but also to prognosis upon diagnosis and risk of death during treatment. Continuing smoking after diagnosis of cancer increase risk of second primary cancer and recurrence. Smoking has been shown to negatively impact outcomes from cancer surgery, affecting postoperative complications. Smoking alter drug metabolism - increases the risk of drug resistance and fluctuation of drug concentrations, of which consequence is poorer response to chemotherapy. Smoking during radiotherapy worsen treatment prognosis too. Quitting smoking can benefit even after a cancer diagnosis, regardless of stage and prognosis and results in immediate and long-term benefits. The evidence is strong enough to incorporate tobacco dependence treatment into routine cancer care, but despite general consensus on the importance of smoking cessation, particularly for patients with cancer, many cancer centers report that they fall short of providing consistent, high-quality smoking cessation service.

Title: European Code against Cancer – successes and challenges in promotion and implementation of the recommendations

Paweł Koczkodaj
The Maria Sklodowska-Curie Institute –Oncology Centre
Poland

Statement of the Problem: European Code against Cancer (ECAC) is an initiative of the European Commission launched in 1987. Currently, in the 4th ECAC's edition there are 12 recommendations on how in simple way reducing the cancer risk. International Agency for Research on Cancer estimates that if all European will follow ECAC re

Methodology & Theoretical Orientation: In 2015 and 2017, the Association of European Cancer Leagues conducted a CAWI survey (Computer-Assisted Web Interview), and it's follow-up which assessed attitudes and perception of the ECAC's recommendations by citizens of Finland, France, Poland, Spain, Great Britain. In 2017, a group of five countries was extended by Hungary, Portugal and Ireland. A representative sample of participants (over 18 years of age) was obtained in each country. The final cohort of respondents numbered 8,171 people (1,003 people in Poland). The obtained data was analyzed taking into account the gender, age and nationality of the participants

Title: Coexistence of lung cancer with Mycobacteria

Abdulrahman Hakami
Jazan University
Saudi Arabia

Background: Pulmonary carcinoids are included in the group of neuroendocrine tumors and derive from pulmonary neuroendocrine cells. The incidence of these tumors is increasing, but disease awareness remains low among clinicians. The synchronous presentation of lung cancer and mycobacterial infection is well known but the combination of pulmonary carcinoid and mycobacterial infection is rare. We treated a 45-year-old female who presented with recurrent pneumonia. Chest X-ray showed a consolidation in the left upper lobe. The patient was treated with various courses of antibiotics without full recovery after six months. CT scan demonstrated a central mass in the left upper lobe. Bronchoscopy revealed an endobronchial, well-defined lesion that totally obstructed the left upper lobe bronchus. Bronchial biopsy showed typical carcinoid tumor. Rigid bronchoscopy with electrocautery was attempted, but we were unable to radically remove the tumor. Therefore lobectomy was performed. The surgical pathology specimen showed atypical bronchial carcinoid and consolidations in the lung parenchyma with granulomatous inflammation distally of the bronchial obstruction. Ziehl-Neelsen staining demonstrated acid fast bacilli indicative of mycobacterial infection.

SPEAKER SLOTS AVAILABLE

Abstract

EuroSciCon

Title: Stem Cells in Acute Lymphoblastic Leukemia and In-Vitro Assessment of the Effect of Parthenolide

Hessah Alsulami
Arabian Gulf University
Saudi Arabia

Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, representing around one-third of all childhood malignancies. In Saudi Arabia ALL accounts for around 35% of all childhood cancers. Despite a high cure rate, some cases relapse. Current drug efficacy studies focus on reducing leukemia cell burden. However, if drugs have limited effects on LSCs, these cells may expand and eventually cause relapse. The experimental anti-leukemic drug parthenolide (PTL) acts by inhibiting transcription factor nuclear kappa B (NF□B), activating p53 and increasing reactive oxygen species (ROS) in leukemic cells. In the present study we assessed the in vitro effect of PTL on immuno-phenotypically defined leukemic stem cells (LSCs) and normal hematopoietic stem cells (HSCs). Because NF□B is constitutively active in LSC, and PTL is a potent inhibitor for it, we also investigated the expression of activated NF□B (NF□Bp65) in selected samples.

Title: Personalized & Precision Medicine (PPM) as a model of Healthcare Services of the next-step generation to secure he National Stability and The Biosafety

Sergey Suchkov
Sechenov University
Russia

A new systems approach to diseased states and wellness result in a new branch in the healthcare services, namely, personalized medicine (PM). To achieve the implementation of PM concept into the daily practice including clinical cardiology, it is necessary to create a fundamentally new strategy based upon the subclinical recognition of bioindicators (biopredictors and biomarkers) of hidden abnormalities long before the disease clinically manifests itself. Each decision-maker values the impact of their decision to use PM on their own budget and well-being, which may not necessarily be optimal for society as a whole. It would be extremely useful to integrate data harvesting from different databanks for applications such as prediction and personalization of further treatment to thus provide more tailored measures for the patients and persons-at-risk resulting in improved outcomes whilst securing the healthy state and wellness, reduced adverse events, and more cost effective use of health care resources.

Title: Impact of real world data on changing treatment policies for breast cancer

Abdalla Abotaleb
World Health Organization

Due to accumulation of real world data through years raised a need for health care system to use these data for enhance, modify, even change polices for treatment and services. With incidence of breast cancer in low middle income country like Egypt which is the most prevalent cancer among women in Egypt, representing 18.9% of total cancer cases (35.1% in women and 2.2% in men) with an age-adjusted rate of 49.6 per 100.000 populations stages III and IV constitute 68% of all breast cancer cases. The previous feature of disease lead to economic burden on budget for the health care system and raise the question how can we use real world data to enhance & modify Treatment polices

SPEAKER SLOTS AVAILABLE

Abstract

EuroSciCon

Title: Knowledge, Attitude And Practice Of Pap Smear Among Female Nurses In Usmanu Danfodiyo University Teaching Hospital, Sokoto

Bawa-Muhammad Taiwo Hassanat
Usmanu Danfodiyo University Teaching Hospital

Carcinoma of the cervix is the commonest malignancy of the female genital tract in the developing countries. Worldwide, cervical cancer is the second most common (12%) cancer in women. This study was aimed to determine the knowledge, attitude and practice of Pap smear among female nurses in a tertiary institution. A descriptive study was carried out using 217 questionnaires to screen female nurses out of which 200 were retrieved. Respondents were selected using convenience sampling technique, structured questionnaires was used in obtaining the data and analyzed with percentage and distribution tables. The findings of the study revealed that nurses have adequate information about cervical cancer, available screening tests, the purpose of screening, the major risk factors and symptoms of cancer cervix. 85% believed that cancer of cervix is preventable and curable if detected early. 66% never advised clients to have it, Very few, 12% ever had a pap smear and the common reasons offered for not screened were 31% said they have no symptom of cervical cancer. 48.2% who did the smear did it voluntary, 11.5% had lost relations to cancer of the cervix and 91% had knowledge about HPV vaccine.

Title: The impact of social marketing based intervention on educating esophageal cancer preventive behaviors

Davoud Shojaeizadeh
Tehran University of Medical Sciences

Esophageal cancer is one of the most widespread disease in Golestan Province , Iran. To identify risk factors a lot of research has been done. Because health workers have successful experiences of health education. The purpose of this study is to use social marketing to influence health workers in order to educate cancer prevention contents. A qualitative study was conducted. The process has been done through Focus Group Discussion that includes six meetings to extract the health worker's opinions. A questionnaire was developed to assesses knowledge, self –efficacy and behavior. The findings the study indicated that there was significant difference between interventional group and control group in behaviors. The Paired T-Test results showed that after intervention there was positive behavioral change in groups. The findings of the study indicated that the apparent increase in Mean Scores in intervention group is significant. Analysis of Covariance was used to Mitigate the effects of variable Pre-test. The Mean of knowledge, attitude, self-efficacy and behaviors of health workers in intervention group was more than control group.

Title: Efficacy of oral immunotherapy in a case of metastatic breast cancer

Tarang Krishna
Dr. Krishna's Cancer Healer Center

Breast cancer is one of the most common cancers in women. World Health Organization estimated the number of diagnosed breast cancer cases at approximately 2.1 million in 2018. This equals to about 11.6% of the total cancer incidence burden. Globally, the incidence rates of breast cancer are much higher as compared to other cancers. Such high prevalence of breast cancer calls for an effective treatment that is able to resolve the condition permanently. Although the best form of resolution is early diagnosis but an assured treatment should be sought as most of the cases get detected in advanced stages. Most of the patients undergo surgery which is coupled with either adjuvant or neoadjuvant chemotherapy and in some cases radiotherapy. The potential side effects of chemotherapy and radiotherapy make them a non viable option. The treatments of hormone therapy and targeted therapy are also not devoid of side effects.

SPEAKER SLOTS AVAILABLE

EuroSciCon

Clinical Oncology and Molecular Diagnostics



June 11- 13, 2018
Dublin, Ireland

EuroSciCon

Clinical Oncology 2018

Agenda Day 1: June 11, 2018

Beech Suite

08:30-09:30 **Registrations**

09:30-09:50 Opening Ceremony

Keynote Forum

09:50-10:00 Introduction

10:00-10:40 **Title: Surgery of brain metastases: New challenges at the era of molecular biology**

Metellus Philippe, Clairval Hospital Center, France

10:40-11:20 **Title: The DNA sequencing revolution and its' impact on clinical oncology**

David I Smith, Mayo Clinic Center, USA

Networking & Refreshment Break 11:20-11:40 @ Foyer

11:40-12:20 **Title:Current treatment option of Chronic Myeloid Leukemia (CML): Focusing on Radiotinib**

Young Rok Do, Keimyung University School of Medicine, Korea

12:20-13:00 **Title: Proton Therapy – The current situation**

Karol Sikora, Proton Partners International Ltd, UK

Group Photo 13:00- 13:10

Lunch Break 13:10-14:10 @ Peacock Restaurant

WorkShop

14:10-15:00 **Title: Cases that haunts you**

Miral Mohammed Mashhour, King Fahad Specialist Hospital, Dammam, Saudi Arabia

Session Introduction

Sessions: Organ Specific Cancer | Molecular Diagnosis and Diagnostics | Cancer Therapy

Session Chair: Juan Pablo Marquez Manriquez, Sonora Cancer Research Center (CICS USA), USA

Session Co-Chair: Julie Smith Gagen, University of Nevada, USA

15:00-15:25 **Title:Pseudo-relapse and cancer stem cells in ovarian cancer**

Martin Orlando Rosas Delgado, Sonora Cancer Research Center (CICS Sonora), Mexico

15:25-15:50 **Title: Multipeptide immunotherapy plus immunogenic chemotherapy in refractory cancer**

Juan Pablo Marquez Manriquez, Sonora Cancer Research Center (CICS USA), USA

15:50-16:15 **Title: Utility Of molecular profiling for diagnosing patients with cancer of unknown primary in a population-based cohort**

Julie Smith Gagen, University of Nevada, USA

Networking & Refreshment Break 16:15-16:35 @ Foyer

16:35-17:00	**Title: Pre-clinical analysis of the feasibility of tumour infiltrating lymphocyte therapy for paediatric brain tumours** Gray Kueberuwa, University of Manchester, UK
17:00-17:25	**Title:Adolescent obesity and adult male breast cancer in a cohort of 1,382,093 men** Lital Keinan Boker, Ministry of Health, Israel; University of Haifa, Israel
17:25-17:50	**Title: Oral Squamous Cell Carcinoma (OSCC) staging system: What other prognostic factors should be considered** Esam Ahmed Z Omar, Taibah University, Saudi Arabia

Agenda Day 2: June 12, 2018

Beech Suite

Keynote Forum

10:00-10:40	**Title: The clinical importance and immunomodulation of the tumor microenvironment** Alejandro Camacho Hernandez , Sonora Cancer Research Center (CICS Sonora), Mexico
10:40-11:20	**Title: Desensitization of HLA donor-specific antibodies results in high engraftment rates in patient undergoing allogeneic hematopoietic stem cell transplantation** Douglas E Gladstone, Johns Hopkins University, USA

Networking & Refreshment Break 11:20-11:40 @ Foyer

11:40-12:20	**Title: Effects of the holocaust on long-term health outcomes in the survivors and their offspring** Lital Keinan Boker, Ministry of Health, Israel ; University of Haifa, Israel

Session Introduction

Sessions: Clinical Oncology | Cancer Diagnosis and Screening | Cancer Drugs and Vaccines | Cancer Biomarkers | Chemotherapy

Session Chair: Chair: David I Smith, Mayo Clinic Centre, USA

Session Co-Chair: Miral Mohammed Mashhour, King Fahad Specialist Hospital, Dammam, Saudi Arabia

12:20-12:45	**Title: Tumor Heterogeneity Imaging (THI): Initial experience in the evaluation of brain gliomas** Gloria J Guzman Perez Carrillo, University of Arizona , USA
12:45-13:10	**Title: Using different next generation sequencing technologies to study the role of human papillomavirus integration in the development of cancer** David I Smith, Mayo Clinic Centre, USA

Lunch Break 13:10-14:10 @ Peacock Restaurant

14:10-14:35	**Title: Immune infiltration evaluation induced by peptides in the test of DTH** Jose Antonio Matute Briceno, CICs - Sonora Cancer Research Center, Mexico
14:35-15:00	**Title: Value of Ki67 in locally advanced breast cancer treated with neoadjuvant chemotherapy** Miral Mohammed Mashhour, King Fahad Specialist Hospital, Dammam, Saudi Arabia
15:00-15:25	**Title: Development of PI3K inhibitor Copanlisib – New insights and outlook** Ningshu Liu, Bayer AG, Germany

15:25-15:50	**Title: Current concepts and future of salivary markers for diagnosing Oral Squamous Cell Carcinoma (OSCC): A review and meta-analysis of relevant published studies** Esam Ahmed Z Omar, Taibah University, Saudi Arabia

Networking & Refreshment Break 15:50-16:10 @ Foyer

Poster Presentations 16:10- 17:00@ Foyer

Poster Judge: Douglas E Gladstone, Johns Hopkins University, USA

CO-01	**Title: Clinical immunogenic chemotherapy in refractory sarcoma** Pedro Alejandro Lucero Diaz, Sonora Cancer Research Center (CICS Sonora), Mexico
CO-02	**Title:Bendamustine shows low Swain-Scott s-constant, nucleophilic selectivity, a basis for marked and prolonged myelosuppression.** Colin Paul Spears, California Northstate University College of Medicine, USA
CO-03	**Title: Targeting protein phosphatase methylesterase 1 to induce apoptosis in NSCLC cells through its ubiquitylation and proteasomal degradation** Wei Lin Yen ,Cardinal Tien Hospital, Taiwan
CO-04	**Title: Survey of useful biomarkers for clinicopathologic characteristics and prognosis of Renal cell carcinoma (RCC)** Mei-Yin Su, National Defense Medical Center, Taiwan
CO-05	**Title: Solution proposed to a 2000-year-old problem in oncology** Michael Retsky, Harvard TH Chan School of Public Health, USA
CO-06	**Title: Chimerism monitoring of pediatric oncology patients after hematopoietic stem cell transplantation using STR analysis** Ebru Dündar Yenilmez , Cukurova University, Turkey

Agenda Day 3: June 13, 2018

Extended Networking & Lunch 12:30-14:00 @ Peacock Restaurant

Mark your Calendar

5th Edition of International Conference on

Clinical Oncology and Molecular Diagnostics

June 17-18, 2019 Rome, Italy

E-mail: clinicaloncology@eurosciconmeeting.org; clinicaloncology@eurosciconconferences.com
Website: oncology.euroscicon.com